Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Know Your Investor: Catalio Capital Management (November’24 Edition)
Know Your Investor: Catalio Capital Management (November’24 Edition)
Shots: A New York-based venture capital fund, Catalio Capital Management invests in breakthrough MedTech and innovative healthcare companies globally In 2023, Catalio Capital participated in eight funding rounds and invested approximately $1.82B to add 22 companies to its portfolio For a curated report on a specific investor or venture capital firm, reach out to us…
November 7, 2024
Key Biosimilars Events of October 2024
Key Biosimilars Events of October 2024
Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        The major highlights were the US FDA’s approval of Dong-A ST’s Imuldosa…
November 5, 2024
New Drug Designations - September 2024
New Drug Designations – September 2024
Shots:   PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA, Health Canada and EMA.  The September 2024 report covers regulatory designations for 42 drugs and 1 device, including 16 small molecules, 6 biologics, 12 cell and gene therapies, and 1 device, among others.  Significant trends this month…
October 29, 2024
EMA Marketing Authorization of New Drugs in September 2024
EMA Marketing Authorization of New Drugs in September 2024
Shots:    The EMA’s CHMP has granted positive opinion to 4 Biologics and 1 New Chemical Entity in September 2024, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were AbbVie’s Elahere to treat Ovarian Cancer and Pfizer’s Hympavzi for Hemophilia A and B  PharmaShots has compiled a list of 3 drugs that have been…
October 24, 2024
The US FDA New Drug Approvals in September 2024
The US FDA New Drug Approvals in September 2024
Shots:      PharmaShots has compiled a list of US FDA-approved drugs in the month of September 2024      The US FDA has approved a total of 7 new drugs including 4 new molecular entities and 3 biologics leading to the treatment of patients and advances in the healthcare industry        The major highlighted drugs were Roche’s Tecentriq Hybreza & Ocrevus Zunovo for…
October 22, 2024
Know Your Investor- Samsara Biocapital (October’24 Edition)
Know Your Investor: Samsara Biocapital (October’24 Edition)
Shots:   A California-based venture capital fund, Samsara Biocapital partners with medical companies and scientists to infuse cutting-edge innovations in medicines   In 2023, Samsara participated in five funding rounds and invested around $2.3B to add 19 companies to its portfolio   For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com …
October 17, 2024
Disease of the Month – Psoriatic arthritis
Disease of the Month – Psoriatic arthritis
Shots: Psoriatic arthritis is a chronic inflammatory condition characterized by joint pain, stiffness and swelling  In this reprise of our Disease of the Month report, we present an enlightening description of Psoriatic arthritis with a thorough study of epidemiology, market size, disease management, potential medicines, patient advocacy groups, and the key players involved     For a…
October 16, 2024
Key Biosimilars Events of September 2024
Key Biosimilars Events of September 2024
Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        The major highlights were the US FDA’s approval of Samsung Bioepis and…
October 3, 2024
PharmaShots' Key Highlights of Third Quarter 2024
PharmaShots’ Key Highlights of Third Quarter 2024
Shots: The third quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Eli Lilly's acquisition of Morphic Holdings for ~$3.2B This quarter also showcased multiple clinical trial results including Roche's P-I Study Data of CT-996 to treat Obesity Our…
October 1, 2024
New Drug Designations - August 2024
New Drug Designations – August 2024 
Shots:   PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. August month’s report includes designations allotted to 10 small molecules, 9 biologics, 7 cell & gene therapies, 1 vaccine, 2 radiopharmaceutical, 1 peptide, 1 antineoplastic and 2 devices   In August 2024, Invenra’s INV724 received the…
September 25, 2024
Load more